PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio.
Cytosorbents Corporation (NASDAQ:CTSO ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Adanna Alexander - IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Tom Kerr - Zacks Small-Cap Research Operator Thank you for standing by. My name is Catherine, and I will be your conference operator today.
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024.
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J.
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2024 operating and financial results after the market close on Tuesday, August 13, 2024.
PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of its newly redesigned and consolidated website at www.cytosorbents.com.
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that on June 28, 2024, the Company entered into a new $20 million credit facility with Avenue Capital Group, including its Avenue Venture Opportunities Fund, L.P.
CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript
Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript
Cytosorbents Corporation. (NASDAQ:CTSO ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Taylor Devlin - Revenue Accountant Phillip Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Interim Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christopher Cramer - Senior Vice President of Business Development Irina Kulinets - Senior Vice President of Regulatory Conference Call Participants Joshua Jennings - TD Cowen Laura Suriel - Alliance Global Partners Sean Lee - H.C.